After stem cells, I was on immunosuppressants for months, but it's not clear to me how the DCVax aimed at transplantation would be made, and where they'd be administered. In that there is no tumor being removed, would they be made like DCVax-Direct, or in the case where an organ is being replaced, would they use the existing organ to make something more like DCVax-L.
In leukemia, which was my case, I would think the DCVax product would just enter the bloodstream. In others, would they be injected into the replaced organ?
I'm just looking to understand how this would be done, not denying its possibility.
For now, concentrating on cancer is what I believe is the key to success. If what we've developed can be applied elsewhere, I'd prefer the company to license it to others with that expertise and have a royalty stream based on their success rather than trying to do too many things at once.
Gary
Bullish
Market Data 
Markets 
AI
